Treats partial-onset seizures. Sold as Vimpat, Motpoly Xr. Every FDA application for this active ingredient: 4 branded and 46 generic.
As of Nov 13, 2026, FDA lists 50 applications for Lacosamide (sold as Vimpat, Motpoly Xr), first approved Oct 28, 2008, with 25 new uses approved and 0 published complete response letters.
| Lacosamide | Part D | $98.7M | -11% | 136,432 |
| Vimpat | Part D | $56.4M | -13% | 4,592 |
| Motpoly XR | Part D | $2.5M | +547% | 426 |
| Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPainful Diabetic Neuropathy (PDN), Diabetic Nephropathies · University of Michigan | Phase 4 | Not yet recruiting | Aug 31, 2026 |
| Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.Bipolar Affective Disorder · University of Sao Paulo | Phase 3 | Recruiting | Feb 17, 2026 |
| Lacosamide Intravenous Injection for Emergency Termination of Status EpilepticusEpilepsy, Status Epilepticus · Second Affiliated Hospital of Guangzhou Medical University | — | Not yet recruiting | May 13, 2025 |
| Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic NeuralgiaHerpes Zoster (HZ), Post Herpetic Neuralgia (PHN) · CMH Kharian Medical College | Not applicable | Recruiting | May 13, 2025 |
| Seizure Prevention in Traumatic Brain Injury With Levetiracetam and LacosamideTraumatic Brain Injury · Wake Forest University Health Sciences | Phase 4 | Recruiting | Mar 10, 2025 |
| Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal NeuralgiaTrigeminal Neuralgia · Hospital Universitari de Bellvitge | — | Recruiting | Feb 28, 2025 |
| Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)Coma, Electrographic Status Epilepticus · University of Twente | Not applicable | Recruiting | Aug 12, 2024 |
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic PancreatitisChronic Pain, Chronic Pain Syndrome · Indiana University | Phase 1 | Active, not recruiting | Nov 3, 2022 |
| Oct 28, 2008 | VimpatNDA 22253 · New molecular entity | Ucb Inc | 34 | Marketed |
| Oct 28, 2008 | VimpatNDA 22254 · New dosage form | Ucb Inc | 30 | Marketed |
| Apr 20, 2010 | VimpatNDA 22255 · New dosage form | Ucb Inc | 27 | Marketed |
| Mar 17, 2022 | LacosamideANDA 204787 | Hetero Labs Ltd V | 5 | Marketed |
| Mar 17, 2022 | LacosamideANDA 204857 | Amneal Pharms | 3 | Discontinued |
| Mar 17, 2022 | LacosamideANDA 204921 | Msn Labs Pvt Ltd | 1 | Marketed |
| Mar 17, 2022 | LacosamideANDA 204974 | Alembic | 0 | Marketed |
| Mar 17, 2022 | LacosamideANDA 205031 | Sun Pharm | 4 | Marketed |
| Mar 17, 2022 | LacosamideANDA 205237 | Sciegen Pharms | 2 | Marketed |
| Mar 17, 2022 | LacosamideANDA 205006 | Glenmark Pharms Ltd | 3 | Marketed |
| Mar 17, 2022 | LacosamideANDA 208308 | Regcon Holdings | 4 | Marketed |
| Mar 31, 2022 | LacosamideANDA 214695 | Alkem Labs Ltd | 4 | Marketed |
| Apr 7, 2022 | LacosamideANDA 214301 | Regcon Holdings | 0 | Marketed |
| May 3, 2022 | LacosamideANDA 214677 | Fresenius Kabi USA | 1 | Marketed |
| May 19, 2022 | LacosamideANDA 214672 | Alkem Labs Ltd | 1 | Marketed |
| May 31, 2022 | LacosamideANDA 209301 | Hetero Labs Ltd Iii | 2 | Marketed |
| Jun 29, 2022 | LacosamideANDA 209465 | Zydus Pharms | 4 | Marketed |
| Jul 12, 2022 | LacosamideANDA 205011 | Accord Hlthcare | 2 | Discontinued |
| Aug 26, 2022 | LacosamideANDA 216151 | Novitium Pharma | 2 | Marketed |
| Sep 14, 2022 | LacosamideANDA 216335 | Aspiro | 1 | Marketed |
| Sep 19, 2022 | LacosamideANDA 215628 | Gland | 1 | Marketed |
| Sep 23, 2022 | LacosamideANDA 214567 | Apotex | 1 | Discontinued |
| Sep 26, 2022 | LacosamideANDA 206355 | Apotex | 3 | Discontinued |
| Jan 5, 2023 | LacosamideANDA 204855 | Actavis Labs Fl Inc | 0 | Discontinued |
| Jan 5, 2023 | LacosamideANDA 204994 | Aurobindo Pharma Ltd | 5 | Marketed |
| Feb 6, 2023 | LacosamideANDA 216461 | Pharmazone | 0 | Marketed |
| Feb 9, 2023 | LacosamideANDA 215979 | Msn | 0 | Marketed |
| May 4, 2023 | Motpoly XrNDA 216185 · New dosage form | Aucta | 1 | Marketed |
| Nov 13, 2023 | LacosamideANDA 216670 | Apotex | 1 | Marketed |
| Dec 15, 2023 | LacosamideANDA 204947 | Zydus Pharms | 0 | Discontinued |
| Dec 22, 2023 | LacosamideANDA 215379 | Msn | 0 | Marketed |
| Jan 24, 2024 | LacosamideANDA 209224 | Aurobindo Pharma Ltd | 2 | Marketed |
| Feb 13, 2024 | LacosamideANDA 217311 | Hainan Poly | 0 | Marketed |
| Mar 25, 2024 | LacosamideANDA 217718 | Dr Reddys | 0 | Marketed |
| Mar 27, 2024 | LacosamideANDA 204839 | Amneal Pharms | 0 | Discontinued |
| Apr 2, 2024 | LacosamideANDA 218014 | Pharmazone | 0 | Marketed |
| Apr 5, 2024 | LacosamideANDA 216806 | Hikma | 0 | Marketed |
| May 15, 2024 | LacosamideANDA 215154 | Chartwell Rx | 0 | Marketed |
| May 24, 2024 | LacosamideANDA 208466 | Macleods Pharms | 0 | Marketed |
| Sep 4, 2024 | LacosamideANDA 213109 | Unichem | 0 | Marketed |
| Oct 9, 2024 | LacosamideANDA 214960 | Somerset Theraps LLC | 0 | Marketed |
| Nov 14, 2024 | LacosamideANDA 218464 | Acella | 0 | Marketed |
| May 23, 2025 | LacosamideANDA 218706 | Op Nanopharma | 0 | Marketed |
| Jun 26, 2025 | LacosamideANDA 219699 | Ajenat Pharms | 0 | Marketed |
| Jan 21, 2026 | LacosamideANDA 220268 | Glenmark Pharms | 0 | Marketed |
| Jan 29, 2026 | LacosamideANDA 220386 | Regcon Holdings | 0 | Marketed |
| May 21, 2026 | LacosamideANDA 220366 | Adaptis | 0 | Discontinued |
| Jun 15, 2026 | LacosamideANDA 217596 | Prod Development | 0 | Marketed |
| — | LacosamideANDA 204980 | Glenmark Pharms Ltd | 0 | Discontinued |
| — | LacosamideANDA 204999 | Teva Pharms USA | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Alembic
Fresenius Kabi USA
Zydus Pharms
Accord Hlthcare
Novitium Pharma
Apotex
Hikma